Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer
Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT...
Saved in:
Published in | Gynecologic oncology Vol. 165; no. 1; pp. 14 - 22 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.04.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC).
Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT.: for PSOC: Carboplatin-Pegylated-Liposomal-Doxorubicin (PLD) or Carboplatin-Gemcitabine; for PROC: PLD, Topotecan, Paclitaxel or Gemcitabine.
160 patients (60 with PSOC and 100 with PROC) were randomized 2:1 to OLA (n = 107) or CT (n = 53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% (26/107) and 28.3% (15/53), respectively). Clinical benefit rate (≥ 12 weeks) was similar with 54.2% (58/107) and 56.6% (30/53), respectively. In PSOC, ORR was 35.0% (14/40) and 65.0% (13/20) for OLA and CT (p = 0.053); in PROC, ORR was 17.9% (12/67) and 6.1% (2/33) for OLA and CT (p = 0.134). ORR in heavily pretreated PROC (>4 prior lines) was 22.9% (8/35) with OLA versus 0% (0/14) for CT. ORR of 35.7% (5/14) and 13.2% (7/53) was observed in BRCA-mutated and -wildtype PROC cases, respectively. Median PFS in PROC was not significantly different with 2.9 months (95% CI 2.8–5.1 in the OLA group versus 3.8 months (95% CI 3.0–6.4) in the CT group (hazard ratio [HR] 1.11 [95% CI 0.72–1.78]; log-rank p = 0.600).
OLA monotherapy showed overall an equal response rate in relapsed ovarian cancer compared with CT. In PROC, ORR and TFST tended to be higher with OLA than with CT. In heavily pretreated patients (four lines or more) with PROC disease, OLA treatment seemed to be more effective than CT.
•Phase II randomized study of olaparib monotherapy versus chemotherapy in recurrent ovarian cancer•Objective response rate was overall similar in the total study (n = 160) for olaparib and chemotherapy•In platinum-sensitive disease the response rate was numerically higher with chemotherapy•Progression free survival, clinical benefit rate and overall survival were overall not significantly different.•In platinum-resistant ovarian cancer with ≥4 prior lines, olaparib seemed to be more effective than chemotherapy. |
---|---|
AbstractList | OBJECTIVEComparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). METHODSPatients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT.: for PSOC: Carboplatin-Pegylated-Liposomal-Doxorubicin (PLD) or Carboplatin-Gemcitabine; for PROC: PLD, Topotecan, Paclitaxel or Gemcitabine. RESULTS160 patients (60 with PSOC and 100 with PROC) were randomized 2:1 to OLA (n = 107) or CT (n = 53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% (26/107) and 28.3% (15/53), respectively). Clinical benefit rate (≥ 12 weeks) was similar with 54.2% (58/107) and 56.6% (30/53), respectively. In PSOC, ORR was 35.0% (14/40) and 65.0% (13/20) for OLA and CT (p = 0.053); in PROC, ORR was 17.9% (12/67) and 6.1% (2/33) for OLA and CT (p = 0.134). ORR in heavily pretreated PROC (>4 prior lines) was 22.9% (8/35) with OLA versus 0% (0/14) for CT. ORR of 35.7% (5/14) and 13.2% (7/53) was observed in BRCA-mutated and -wildtype PROC cases, respectively. Median PFS in PROC was not significantly different with 2.9 months (95% CI 2.8-5.1 in the OLA group versus 3.8 months (95% CI 3.0-6.4) in the CT group (hazard ratio [HR] 1.11 [95% CI 0.72-1.78]; log-rank p = 0.600). CONCLUSIONOLA monotherapy showed overall an equal response rate in relapsed ovarian cancer compared with CT. In PROC, ORR and TFST tended to be higher with OLA than with CT. In heavily pretreated patients (four lines or more) with PROC disease, OLA treatment seemed to be more effective than CT. Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT.: for PSOC: Carboplatin-Pegylated-Liposomal-Doxorubicin (PLD) or Carboplatin-Gemcitabine; for PROC: PLD, Topotecan, Paclitaxel or Gemcitabine. 160 patients (60 with PSOC and 100 with PROC) were randomized 2:1 to OLA (n = 107) or CT (n = 53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% (26/107) and 28.3% (15/53), respectively). Clinical benefit rate (≥ 12 weeks) was similar with 54.2% (58/107) and 56.6% (30/53), respectively. In PSOC, ORR was 35.0% (14/40) and 65.0% (13/20) for OLA and CT (p = 0.053); in PROC, ORR was 17.9% (12/67) and 6.1% (2/33) for OLA and CT (p = 0.134). ORR in heavily pretreated PROC (>4 prior lines) was 22.9% (8/35) with OLA versus 0% (0/14) for CT. ORR of 35.7% (5/14) and 13.2% (7/53) was observed in BRCA-mutated and -wildtype PROC cases, respectively. Median PFS in PROC was not significantly different with 2.9 months (95% CI 2.8-5.1 in the OLA group versus 3.8 months (95% CI 3.0-6.4) in the CT group (hazard ratio [HR] 1.11 [95% CI 0.72-1.78]; log-rank p = 0.600). OLA monotherapy showed overall an equal response rate in relapsed ovarian cancer compared with CT. In PROC, ORR and TFST tended to be higher with OLA than with CT. In heavily pretreated patients (four lines or more) with PROC disease, OLA treatment seemed to be more effective than CT. Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC). Patients with measurable disease and ≥ 1 prior line of chemotherapy (CT) were randomized 2:1 to OLA (300 mg tablets, BID) or physician's choice CT.: for PSOC: Carboplatin-Pegylated-Liposomal-Doxorubicin (PLD) or Carboplatin-Gemcitabine; for PROC: PLD, Topotecan, Paclitaxel or Gemcitabine. 160 patients (60 with PSOC and 100 with PROC) were randomized 2:1 to OLA (n = 107) or CT (n = 53). Baseline characteristics were similar between both arms. Overall objective response rate (ORR) for OLA and CT were similar (24.3% (26/107) and 28.3% (15/53), respectively). Clinical benefit rate (≥ 12 weeks) was similar with 54.2% (58/107) and 56.6% (30/53), respectively. In PSOC, ORR was 35.0% (14/40) and 65.0% (13/20) for OLA and CT (p = 0.053); in PROC, ORR was 17.9% (12/67) and 6.1% (2/33) for OLA and CT (p = 0.134). ORR in heavily pretreated PROC (>4 prior lines) was 22.9% (8/35) with OLA versus 0% (0/14) for CT. ORR of 35.7% (5/14) and 13.2% (7/53) was observed in BRCA-mutated and -wildtype PROC cases, respectively. Median PFS in PROC was not significantly different with 2.9 months (95% CI 2.8–5.1 in the OLA group versus 3.8 months (95% CI 3.0–6.4) in the CT group (hazard ratio [HR] 1.11 [95% CI 0.72–1.78]; log-rank p = 0.600). OLA monotherapy showed overall an equal response rate in relapsed ovarian cancer compared with CT. In PROC, ORR and TFST tended to be higher with OLA than with CT. In heavily pretreated patients (four lines or more) with PROC disease, OLA treatment seemed to be more effective than CT. •Phase II randomized study of olaparib monotherapy versus chemotherapy in recurrent ovarian cancer•Objective response rate was overall similar in the total study (n = 160) for olaparib and chemotherapy•In platinum-sensitive disease the response rate was numerically higher with chemotherapy•Progression free survival, clinical benefit rate and overall survival were overall not significantly different.•In platinum-resistant ovarian cancer with ≥4 prior lines, olaparib seemed to be more effective than chemotherapy. |
Author | Vanderstichele, Adriaan Salihi, Rawand Olbrecht, Siel Loverix, Liselore Vergote, Ignace Busschaert, Pieter Van Gorp, Toon Concin, Nicole Neven, Patrick Lambrechts, Diether Van Nieuwenhuysen, Els Han, Sileny N. Callewaert, Tiene Berteloot, Patrick |
Author_xml | – sequence: 1 givenname: Adriaan surname: Vanderstichele fullname: Vanderstichele, Adriaan organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 2 givenname: Liselore surname: Loverix fullname: Loverix, Liselore organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 3 givenname: Pieter surname: Busschaert fullname: Busschaert, Pieter organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 4 givenname: Els surname: Van Nieuwenhuysen fullname: Van Nieuwenhuysen, Els organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 5 givenname: Sileny N. surname: Han fullname: Han, Sileny N. organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 6 givenname: Nicole surname: Concin fullname: Concin, Nicole organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 7 givenname: Tiene surname: Callewaert fullname: Callewaert, Tiene organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 8 givenname: Siel surname: Olbrecht fullname: Olbrecht, Siel organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 9 givenname: Rawand surname: Salihi fullname: Salihi, Rawand organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 10 givenname: Patrick surname: Berteloot fullname: Berteloot, Patrick organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 11 givenname: Patrick surname: Neven fullname: Neven, Patrick organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 12 givenname: Diether surname: Lambrechts fullname: Lambrechts, Diether organization: Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Leuven, Belgium – sequence: 13 givenname: Toon surname: Van Gorp fullname: Van Gorp, Toon organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium – sequence: 14 givenname: Ignace surname: Vergote fullname: Vergote, Ignace email: ignace.vergote@uzleuven.be organization: Belgium and Luxembourg Gynaecological Oncology Group (BGOG), Department of Gynaecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35177277$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kE1r3DAQhkVJaTZpf0Gh6NZc7Iwkyx-HHpql3QYWFkJ6FrI87mqxJVfyLji_vko3zbGngeF532GeK3LhvENCPjLIGbDy9pAvvxbncw6c58ByEMUbsmLQyKysZXNBVgANZDWX9SW5ivEAAAIYf0cuhWRVxatqRZYH7To_2ifs6Hp7v7u92-w2mT8xoHOweqC-p37Qkw62paN3ft5j0NNCTxjiMdJpv0RrrHafIzV7bw2mgeMrZh0NmPIx9ftTatGOGu0Mhvfkba-HiB9e5jX5-f3b4_pHtt1t7tdft5kRspkzbEDWrO6wbmUnBJN9V_JW96YoG94bxlpsOU97CTVCoQsoCiFkJXjbsop14prcnHun4H8fMc5qtNHgMGiH_hgVLwU0PFmrEyrOqAk-xoC9moIddVgUA_XsXB3UX-fq2bkCppLzlPr0cuDYjti9Zv5JTsCXM4DpzZPFoKKxmBx0NqCZVeftfw_8AdJ6lh4 |
CitedBy_id | crossref_primary_10_3389_fphar_2024_1416555 crossref_primary_10_2174_1573409920666230907093331 crossref_primary_10_1016_j_ctrv_2023_102601 crossref_primary_10_1016_j_eclinm_2022_101767 crossref_primary_10_2217_fon_2022_0666 crossref_primary_10_3390_cancers15020448 crossref_primary_10_1016_j_ejca_2023_04_020 crossref_primary_10_1016_j_esmoop_2023_101154 crossref_primary_10_3390_ijms231810892 crossref_primary_10_3389_fphar_2023_1162665 crossref_primary_10_1038_s41416_023_02567_6 crossref_primary_10_1053_j_seminoncol_2024_01_001 crossref_primary_10_1186_s12957_023_03027_4 crossref_primary_10_3389_fonc_2022_1071383 crossref_primary_10_3390_cancers14194621 |
Cites_doi | 10.1016/j.ejca.2017.10.030 10.1016/j.ejca.2017.08.029 10.1158/1078-0432.CCR-15-0887 10.1158/1078-0432.CCR-17-1337 10.1016/S1470-2045(18)30786-1 10.1097/IGC.0000000000000478 10.1038/sj.bjc.6601117 10.1016/S1470-2045(19)30029-4 10.1016/S0140-6736(17)33326-3 10.1016/j.ejca.2008.10.026 10.1093/annonc/mdz062 10.1158/1078-0432.CCR-15-2477 10.1016/S0140-6736(18)32552-2 |
ContentType | Journal Article |
Copyright | 2022 Elsevier Inc. Copyright © 2022 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2022 Elsevier Inc. – notice: Copyright © 2022 Elsevier Inc. All rights reserved. |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.ygyno.2022.01.034 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1095-6859 |
EndPage | 22 |
ExternalDocumentID | 10_1016_j_ygyno_2022_01_034 35177277 S0090825822000737 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .1- .55 .FO .GJ .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29I 3O- 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQQT AAQXK AAXUO ABBQC ABFNM ABFRF ABJNI ABLVK ABMAC ABMZM ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AEVXI AFCTW AFFNX AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY AJUYK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG COF CS3 DM4 DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HED HMK HMO HVGLF HZ~ IH2 IHE J1W K-O KOM L7B LCYCR LG5 M29 M41 MO0 N9A O-L O9- OAUVE OQ. OZT P-8 P-9 P2P PC. PH~ Q38 R2- RIG ROL RPZ SAE SCC SDF SDG SDP SES SEW SPCBC SSH SSZ T5K UDS UHS UV1 WUQ X7M XPP Z5R ZGI ZMT ZU3 ZXP ~G- AAXKI AFJKZ AKRWK NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c359t-e905818de8b5d3315fd62bafc4692fc11beb22315508e04a4044335732bb171d3 |
IEDL.DBID | AIKHN |
ISSN | 0090-8258 |
IngestDate | Fri Aug 16 11:44:01 EDT 2024 Thu Sep 26 18:00:01 EDT 2024 Sat Sep 28 08:19:30 EDT 2024 Fri Feb 23 02:41:55 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Recurrence Chemotherapy Olaparib Randomized PARPi Ovarian cancer |
Language | English |
License | Copyright © 2022 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c359t-e905818de8b5d3315fd62bafc4692fc11beb22315508e04a4044335732bb171d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-News-3 content type line 23 |
PMID | 35177277 |
PQID | 2630920958 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2630920958 crossref_primary_10_1016_j_ygyno_2022_01_034 pubmed_primary_35177277 elsevier_sciencedirect_doi_10_1016_j_ygyno_2022_01_034 |
PublicationCentury | 2000 |
PublicationDate | April 2022 2022-04-00 20220401 |
PublicationDateYYYYMMDD | 2022-04-01 |
PublicationDate_xml | – month: 04 year: 2022 text: April 2022 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Gynecologic oncology |
PublicationTitleAlternate | Gynecol Oncol |
PublicationYear | 2022 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | NCI (bb0060) 2017 Colombo, Sessa, Du Bois (bb0025) 2019; 30 LaFargue, Dal Molin, Sood (bb0070) 2019; 20 Timmermans, Sonke, Van de Vijver (bb0010) 2018; 88 Clark, Bradburn, Love (bb0065) 2003; 89 Du Bois, Reuss, Pujade-Lauraine (bb0050) 2015; 25 Allemani, Matsuda, Di Carlo (bb0005) 2018; 391 Melinda, Kirsten, Julia (bb0045) 2016; 22 Lheureux, Gourley, Vergote, Oza (bb0020) 2019; 393 Eisenhauer, Therasse, Bogaerts (bb0055) 2009; 45 Kim, Ison, McKee (bb0030) 2015; 21 Moore, Secord, Geller (bb0040) 2019; 20 Vanderstichele, Busschaert, Olbrecht (bb0015) 2017; 86 Balasubramaniam, Beaver, Horton (bb0035) 2017; 23 Eisenhauer (10.1016/j.ygyno.2022.01.034_bb0055) 2009; 45 LaFargue (10.1016/j.ygyno.2022.01.034_bb0070) 2019; 20 Timmermans (10.1016/j.ygyno.2022.01.034_bb0010) 2018; 88 Du Bois (10.1016/j.ygyno.2022.01.034_bb0050) 2015; 25 NCI (10.1016/j.ygyno.2022.01.034_bb0060) Vanderstichele (10.1016/j.ygyno.2022.01.034_bb0015) 2017; 86 Moore (10.1016/j.ygyno.2022.01.034_bb0040) 2019; 20 Balasubramaniam (10.1016/j.ygyno.2022.01.034_bb0035) 2017; 23 Melinda (10.1016/j.ygyno.2022.01.034_bb0045) 2016; 22 Allemani (10.1016/j.ygyno.2022.01.034_bb0005) 2018; 391 Colombo (10.1016/j.ygyno.2022.01.034_bb0025) 2019; 30 Clark (10.1016/j.ygyno.2022.01.034_bb0065) 2003; 89 Lheureux (10.1016/j.ygyno.2022.01.034_bb0020) 2019; 393 Kim (10.1016/j.ygyno.2022.01.034_bb0030) 2015; 21 |
References_xml | – volume: 45 start-page: 228 year: 2009 end-page: 247 ident: bb0055 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur. J. Cancer contributor: fullname: Bogaerts – volume: 20 start-page: e15 year: 2019 end-page: e28 ident: bb0070 article-title: Exploring and comparing adverse events between PARP inhibitors publication-title: Lancet Oncol contributor: fullname: Sood – volume: 22 start-page: 3764 year: 2016 end-page: 3773 ident: bb0045 article-title: Homologous recombination deficiency (hrd) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer publication-title: Clin. Cancer Res. contributor: fullname: Julia – volume: 21 start-page: 4257 year: 2015 end-page: 4261 ident: bb0030 article-title: FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy publication-title: Clin. Cancer Res. contributor: fullname: McKee – volume: 20 start-page: 636 year: 2019 end-page: 648 ident: bb0040 article-title: Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial publication-title: Lancet Oncol contributor: fullname: Geller – volume: 89 start-page: 781 year: 2003 end-page: 786 ident: bb0065 article-title: Survival analysis part IV: further concepts and methods in survival analysis publication-title: Br. J. Cancer contributor: fullname: Love – volume: 30 start-page: 672 year: 2019 end-page: 705 ident: bb0025 article-title: ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease publication-title: Ann. Oncol. contributor: fullname: Du Bois – volume: 23 start-page: 7165 year: 2017 end-page: 7170 ident: bb0035 article-title: FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation–associated advanced ovarian cancer publication-title: Clin. Cancer Res. contributor: fullname: Horton – volume: 25 start-page: 1328 year: 2015 end-page: 1330 ident: bb0050 article-title: European network of gynaecological oncological trial groups’ requirements for trials between academic groups and industry partners - first update 2015 publication-title: Int. J. Gynecol. Cancer contributor: fullname: Pujade-Lauraine – volume: 391 start-page: 1023 year: 2018 end-page: 1075 ident: bb0005 article-title: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 publication-title: Lancet contributor: fullname: Di Carlo – year: 2017 ident: bb0060 article-title: Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet] contributor: fullname: NCI – volume: 88 start-page: 31 year: 2018 end-page: 37 ident: bb0010 article-title: No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands publication-title: Eur. J. Cancer contributor: fullname: Van de Vijver – volume: 86 start-page: 5 year: 2017 end-page: 14 ident: bb0015 article-title: Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer publication-title: Eur. J. Cancer contributor: fullname: Olbrecht – volume: 393 start-page: 1240 year: 2019 end-page: 1253 ident: bb0020 article-title: Epithelial ovarian cancer publication-title: Lancet contributor: fullname: Oza – volume: 88 start-page: 31 year: 2018 ident: 10.1016/j.ygyno.2022.01.034_bb0010 article-title: No improvement in long-term survival for epithelial ovarian cancer patients: a population-based study between 1989 and 2014 in the Netherlands publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.10.030 contributor: fullname: Timmermans – volume: 86 start-page: 5 year: 2017 ident: 10.1016/j.ygyno.2022.01.034_bb0015 article-title: Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2017.08.029 contributor: fullname: Vanderstichele – volume: 21 start-page: 4257 issue: 19 year: 2015 ident: 10.1016/j.ygyno.2022.01.034_bb0030 article-title: FDA approval summary: Olaparib monotherapy in patients with deleterious germline BRCA-mutated advanced ovarian cancer treated with three or more lines of chemotherapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0887 contributor: fullname: Kim – volume: 23 start-page: 7165 issue: 23 year: 2017 ident: 10.1016/j.ygyno.2022.01.034_bb0035 article-title: FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation–associated advanced ovarian cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-1337 contributor: fullname: Balasubramaniam – volume: 20 start-page: e15 issue: 1 year: 2019 ident: 10.1016/j.ygyno.2022.01.034_bb0070 article-title: Exploring and comparing adverse events between PARP inhibitors publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30786-1 contributor: fullname: LaFargue – volume: 25 start-page: 1328 issue: 7 year: 2015 ident: 10.1016/j.ygyno.2022.01.034_bb0050 article-title: European network of gynaecological oncological trial groups’ requirements for trials between academic groups and industry partners - first update 2015 publication-title: Int. J. Gynecol. Cancer doi: 10.1097/IGC.0000000000000478 contributor: fullname: Du Bois – volume: 89 start-page: 781 issue: 5 year: 2003 ident: 10.1016/j.ygyno.2022.01.034_bb0065 article-title: Survival analysis part IV: further concepts and methods in survival analysis publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6601117 contributor: fullname: Clark – volume: 20 start-page: 636 issue: 5 year: 2019 ident: 10.1016/j.ygyno.2022.01.034_bb0040 article-title: Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30029-4 contributor: fullname: Moore – volume: 391 start-page: 1023 year: 2018 ident: 10.1016/j.ygyno.2022.01.034_bb0005 article-title: Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37513025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries publication-title: Lancet doi: 10.1016/S0140-6736(17)33326-3 contributor: fullname: Allemani – volume: 45 start-page: 228 year: 2009 ident: 10.1016/j.ygyno.2022.01.034_bb0055 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2008.10.026 contributor: fullname: Eisenhauer – volume: 30 start-page: 672 issue: 5 year: 2019 ident: 10.1016/j.ygyno.2022.01.034_bb0025 article-title: ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz062 contributor: fullname: Colombo – volume: 22 start-page: 3764 issue: 15 year: 2016 ident: 10.1016/j.ygyno.2022.01.034_bb0045 article-title: Homologous recombination deficiency (hrd) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2477 contributor: fullname: Melinda – ident: 10.1016/j.ygyno.2022.01.034_bb0060 contributor: fullname: NCI – volume: 393 start-page: 1240 issue: 10177 year: 2019 ident: 10.1016/j.ygyno.2022.01.034_bb0020 article-title: Epithelial ovarian cancer publication-title: Lancet doi: 10.1016/S0140-6736(18)32552-2 contributor: fullname: Lheureux |
SSID | ssj0003012 |
Score | 2.5009499 |
Snippet | Comparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC).
Patients... OBJECTIVEComparison of olaparib (OLA) monotherapy versus chemotherapy in patients with platinum-sensitive (PSOC) or platinum-resistant ovarian cancer (PROC).... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 14 |
SubjectTerms | Chemotherapy Olaparib Ovarian cancer PARPi Randomized Recurrence |
Title | Randomized CLIO/BGOG-ov10 trial of olaparib monotherapy versus physician's choice chemotherapy in relapsed ovarian cancer |
URI | https://dx.doi.org/10.1016/j.ygyno.2022.01.034 https://www.ncbi.nlm.nih.gov/pubmed/35177277 https://search.proquest.com/docview/2630920958 |
Volume | 165 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB7BIlW9IKCvhYJcqVIvTTd-xcmRrgoLW0BCReVm2YlTLRLJit1FWg78dsZOslIPcOBkJUoca2YyM589D4CvhqPNooWKMmWTSKTGbzRJHqnMMeVCRTsPFM_Ok9GVOL2W12sw7HJhfFhlq_sbnR60dXtn0FJzMJ1MfI6vb9ct0cKF8ya1DhtojoTowcbhyXh0vlLIKMNN0fCQNS3TrvhQCPNa_ltWPgmQsVC-k4vnDNRzDmgwREdbsNl6kOSwWeQ2rLlqB96ctWfk72B5aaqivp08uIIMf59cDH4eXxxH9T2NSWjRQeqSIJ713QctQSFsU7CWxAdoLGZktdfxbUZQN6IiwcHdrh6bVMQnwExnOH99j7OYiuRedu7ew9XRrz_DUdQ2WIhyLrN55LJYosEuXGplwTmVZZEwa8ocMTMrc0ot4m50ABHFpC4WRsRCcC4VZ9ZSRQv-AXpVXblPQGLlEhEbmZacC8tyK40v6yNUmiMEdaYP3zuq6mlTR0N3AWY3OjBBeybomGpkQh-SjvL6P3HQqOlffvFLxyeNP4o__TCVqxczzRIeZww9yrQPHxsGrlbCJUWUodTuaz-7B2_9VRPS8xl687uF20dvZW4PYP3HIz1oZdKP48u_4yeT1ekG |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwEB5RkNpeqvJou6WAKyH1QrrxK06OdAUsdBekCiRulp041VYiWbG7SNtDf3vHTrJVD3DgFClPyzOZmc_-Zgbg0HD0WbRQUaZsEonU-IUmySOVOaZcqGjngeL4MhneiItbebsGgy4XxtMqW9vf2PRgrdsz_XY2-9PJxOf4-nbdEj1c2G9SL2DDRwOe1_X1zz-eB2pwUzI85EzLtCs9FEhey5_LyqcAMhaKd3LxmHt6LPwMbuj0Lbxp40dy3AxxE9ZctQUvx-0O-TYsf5iqqO8mv11BBqPzq_63s6uzqH6gMQkNOkhdEkSzvvegJaiCbQLWknh6xmJGVisdX2YELSOaETy4u9Vtk4r49JfpDN9fP-BbTEVyrzn3O3BzenI9GEZte4Uo5zKbRy6LJbrrwqVWFpxTWRYJs6bMETGzMqfUIurG8A8xTOpiYUQsBOdScWYtVbTg72C9qiv3AUisXCJiI9OSc2FZbqXxRX2ESnMEoM704KibVT1tqmjojl72SwchaC8EHVONQuhB0s28_k8ZNNr5px_83MlJ42_i9z5M5erFTLOExxnDeDLtwftGgKuRcEkRYyj18bmfPYBXw-vxSI_OL7_vwmt_pSH3fIL1-f3C7WHcMrf7QS__Al-a6Dg |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Randomized+CLIO%2FBGOG-ov10+trial+of+olaparib+monotherapy+versus+physician%27s+choice+chemotherapy+in+relapsed+ovarian+cancer&rft.jtitle=Gynecologic+oncology&rft.au=Vanderstichele%2C+Adriaan&rft.au=Loverix%2C+Liselore&rft.au=Busschaert%2C+Pieter&rft.au=Van+Nieuwenhuysen%2C+Els&rft.date=2022-04-01&rft.eissn=1095-6859&rft.volume=165&rft.issue=1&rft.spage=14&rft.epage=22&rft_id=info:doi/10.1016%2Fj.ygyno.2022.01.034&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-8258&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-8258&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-8258&client=summon |